Market capitalization | $39.66m |
Enterprise Value | $-7.51m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 2.36 |
EV/Sales (TTM) EV/Sales | -0.40 |
P/S ratio (TTM) P/S ratio | 2.09 |
P/B ratio (TTM) P/B ratio | 0.83 |
Sales growth (TTM) Sales growth | -54.30% |
Turnover (TTM) Turnover | $19.01m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
3 Analysts have issued a Ocuphire Pharma Inc forecast:
3 Analysts have issued a Ocuphire Pharma Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 19 19 |
54%
54%
|
|
Gross income | 19 19 |
54%
54%
|
|
EBITDA | -12 -12 |
165%
165%
|
EBIT (operating result) EBIT | -12 -12 |
165%
165%
|
Net profit | -11 -11 |
160%
160%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Head office | United States |
CEO | George Magrath |
Employees | 14 |
Founded | 2018 |
Website | www.ocuphire.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.